Tracy Alan Bridges
- Type
- Physician · Allopathic & Osteopathic Physicians / Allergy & Immunology
- Where
- Albany, GA
- NPI
- 1386749117
- Received
- $364,257 in 892 records, 2019 to 2025
- As principal investigator
- $1,165,130 of research payments to others in 232 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 190 | $81,412 |
| 2024 | General payment | 169 | $89,401 |
| 2023 | General payment | 146 | $58,854 |
| 2022 | General payment | 96 | $29,070 |
| 2021 | General payment | 97 | $37,125 |
| 2020 | General payment | 91 | $23,755 |
| 2019 | General payment | 103 | $44,638 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 134 | $319,857 |
| Food and Beverage | 656 | $19,777 |
| Travel and Lodging | 89 | $17,781 |
| Consulting Fee | 11 | $6,736 |
| Education | 2 | $103 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | Grifols USA, LLC | $15 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2025 | |
| 2025-12-16 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-12-15 | AstraZeneca Pharmaceuticals LP | $4,720 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-12-12 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | XOLAIR Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-12-11 | AstraZeneca Pharmaceuticals LP | $123 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-12-11 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-11 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-12-10 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | CUTAQUIG Biological, IMMUNOLOGY | 2025 | |
| 2025-12-10 | Takeda Pharmaceuticals U.S.A., Inc. | $13 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-12-09 | CSL Behring | $22 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-12-03 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-11-24 | AstraZeneca Pharmaceuticals LP | $450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-21 | Regeneron Healthcare Solutions, Inc. | $33 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-20 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-19 | CSL Behring | $21 | Food and Beverage | In-kind items and services | Andembry Biological, Hematology | 2025 | |
| 2025-11-13 | PFIZER INC. | $1 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-11-12 | Grifols USA, LLC | $33 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2025 | |
| 2025-11-07 | LEO Pharma Inc. | $24 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-06 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-11-05 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-04 | Takeda Pharmaceuticals U.S.A., Inc. | $26 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-11-03 | AstraZeneca Pharmaceuticals LP | $2,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-30 | AstraZeneca Pharmaceuticals LP | $217 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-30 | AstraZeneca Pharmaceuticals LP | $125 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-30 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-29 | Grifols USA, LLC | $31 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-10-24 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-24 | Pharming Healthcare, Inc. | $14 | Food and Beverage | In-kind items and services | RUCONEST Biological, BIOLOGIC | 2025 | |
| 2025-10-23 | Novartis Pharmaceuticals Corporation | $31 | Food and Beverage | In-kind items and services | XOLAIR Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-22 | CSL Behring | $24 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-10-21 | GlaxoSmithKline, LLC. | $24 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-20 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | CUTAQUIG Biological, IMMUNOLOGY | 2025 | |
| 2025-10-15 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-14 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-10 | ARS Pharmaceuticals Operations, Inc. | $18 | Food and Beverage | In-kind items and services | NEFFY Drug, ALLERGY | 2025 | |
| 2025-10-08 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-10-07 | Takeda Pharmaceuticals U.S.A., Inc. | $18 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-10-04 | GlaxoSmithKline, LLC. | $4 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-09-30 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-25 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-09-25 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | CUTAQUIG Biological, IMMUNOLOGY | 2025 | |
| 2025-09-24 | Ionis Pharmaceuticals, Inc. | $28 | Food and Beverage | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-23 | Regeneron Healthcare Solutions, Inc. | $36 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-18 | AstraZeneca Pharmaceuticals LP | $226 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-18 | AstraZeneca Pharmaceuticals LP | $133 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-11 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-10 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-09 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-09 | CSL Behring | $27 | Food and Beverage | In-kind items and services | Andembry Biological, Hematology | 2025 | |
| 2025-09-04 | AstraZeneca Pharmaceuticals LP | $295 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-04 | AstraZeneca Pharmaceuticals LP | $104 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-09-04 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-08-27 | Incyte Corporation | $18 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-08-20 | Grifols USA, LLC | $23 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2025 | |
| 2025-08-19 | BioCryst US Sales Co., LLC | $29 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2025 | |
| 2025-08-14 | GENZYME CORPORATION | $21 | Food and Beverage | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-08-13 | CSL Behring | $26 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-08-12 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | CUTAQUIG Biological, IMMUNOLOGY | 2025 | |
| 2025-08-12 | Takeda Pharmaceuticals U.S.A., Inc. | $21 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-08-11 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-08-06 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-08-06 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-08-01 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-31 | GENZYME CORPORATION | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-30 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-30 | AstraZeneca Pharmaceuticals LP | $101 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-29 | Regeneron Healthcare Solutions, Inc. | $33 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-28 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-07-28 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-07-26 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-07-25 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-07-24 | AstraZeneca Pharmaceuticals LP | $278 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-07-24 | AstraZeneca Pharmaceuticals LP | $121 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-07-24 | AstraZeneca Pharmaceuticals LP | $95 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-07-24 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-07-22 | Genentech USA, Inc. | $26 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-07-10 | CSL Behring | $25 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-07-08 | AstraZeneca Pharmaceuticals LP | $100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-08 | BioCryst US Sales Co., LLC | $29 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2025 | |
| 2025-07-08 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-07-03 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-02 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-30 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-30 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-26 | AstraZeneca Pharmaceuticals LP | $2,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-26 | AstraZeneca Pharmaceuticals LP | $226 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-26 | AstraZeneca Pharmaceuticals LP | $102 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-26 | AstraZeneca Pharmaceuticals LP | $71 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-25 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-24 | BioCryst US Sales Co., LLC | $32 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2025 | |
| 2025-06-24 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-06-19 | AstraZeneca Pharmaceuticals LP | $114 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-19 | AstraZeneca Pharmaceuticals LP | $102 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-18 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-06-18 | GlaxoSmithKline, LLC. | $0 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-06-16 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-06-10 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-06-10 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-06-06 | GlaxoSmithKline, LLC. | $6 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-06-06 | GlaxoSmithKline, LLC. | $5 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-06-05 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-06-04 | GlaxoSmithKline, LLC. | $0 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-05-29 | Amgen Inc. | $27 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-05-29 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-05-29 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-05-23 | Cycle Pharmaceuticals Inc | $30 | Food and Beverage | Cash or cash equivalent | Sajazir Drug, Immunology | 2025 | |
| 2025-05-23 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-05-22 | LEO Pharma Inc. | $19 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-05-21 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-21 | AstraZeneca Pharmaceuticals LP | $450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-21 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-20 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-20 | Takeda Pharmaceuticals U.S.A., Inc. | $19 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-05-13 | AstraZeneca Pharmaceuticals LP | $133 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-13 | AstraZeneca Pharmaceuticals LP | $125 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-12 | AstraZeneca Pharmaceuticals LP | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-05-09 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-05-08 | Regeneron Healthcare Solutions, Inc. | $121 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-05-07 | Regeneron Healthcare Solutions, Inc. | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-05-06 | BioCryst US Sales Co., LLC | $32 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2025 | |
| 2025-04-30 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-04-29 | CSL Behring | $27 | Food and Beverage | In-kind items and services | Hizentra Biological, Immunology | 2025 | |
| 2025-04-24 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-04-23 | AstraZeneca Pharmaceuticals LP | $1,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-23 | Takeda Pharmaceuticals U.S.A., Inc. | $17 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-04-22 | ADMA BioManufacturing LLC | $24 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-17 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-17 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-04-16 | Grifols USA, LLC | $25 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2025 | |
| 2025-04-11 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-10 | Regeneron Healthcare Solutions, Inc. | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-07 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-07 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-04-04 | AstraZeneca Pharmaceuticals LP | $147 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-04 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-01 | GENZYME CORPORATION | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-03-26 | AstraZeneca Pharmaceuticals LP | $129 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-26 | Takeda Pharmaceuticals U.S.A., Inc. | $15 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-03-25 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-03-20 | AstraZeneca Pharmaceuticals LP | $294 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-03-20 | AstraZeneca Pharmaceuticals LP | $98 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-03-19 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-03-13 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-13 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-11 | AstraZeneca Pharmaceuticals LP | $2,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-11 | BioCryst US Sales Co., LLC | $29 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2025 | |
| 2025-03-06 | AstraZeneca Pharmaceuticals LP | $127 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-06 | AstraZeneca Pharmaceuticals LP | $106 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-05 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-04 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage (4 payments) | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-04 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-26 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-26 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-25 | ARS Pharmaceuticals Operations, Inc. | $28 | Food and Beverage | In-kind items and services | NEFFY Drug, ALLERGY | 2025 | |
| 2025-02-25 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-02-20 | AstraZeneca Pharmaceuticals LP | $107 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-20 | AstraZeneca Pharmaceuticals LP | $101 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-20 | AstraZeneca Pharmaceuticals LP | $51 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-20 | LEO Pharma Inc. | $23 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-02-20 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-20 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage (4 payments) | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-19 | Grifols USA, LLC | $24 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2025 | |
| 2025-02-18 | AstraZeneca Pharmaceuticals LP | $450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-12 | Grifols USA, LLC | $25 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-02-11 | BioCryst US Sales Co., LLC | $29 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2025 | |
| 2025-02-10 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-06 | AstraZeneca Pharmaceuticals LP | $3,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-06 | AstraZeneca Pharmaceuticals LP | $268 | Travel and Lodging | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-06 | AstraZeneca Pharmaceuticals LP | $98 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-02-05 | PFIZER INC. | $0 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2025 | |
| 2025-02-04 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-01-29 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-01-28 | Takeda Pharmaceuticals U.S.A., Inc. | $20 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-01-27 | AstraZeneca Pharmaceuticals LP | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-01-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2025 | |
| 2025-01-24 | AstraZeneca Pharmaceuticals LP | $189 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-01-24 | AstraZeneca Pharmaceuticals LP | $78 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-01-20 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-01-17 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | EUCRISA Drug, DERMATOLOGY | 2025 | |
| 2025-01-16 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-01-15 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY;INFLAMMATION | 2025 | |
| 2025-01-15 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-01-14 | BioCryst US Sales Co., LLC | $29 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2025 | |
| 2025-01-07 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-01-07 | Takeda Pharmaceuticals U.S.A., Inc. | $10 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2025 | |
| 2025-01-01 | ADMA BioManufacturing LLC | $22 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-12-19 | Regeneron Healthcare Solutions, Inc. | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-12-18 | GENZYME CORPORATION | $33 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-12-12 | AstraZeneca Pharmaceuticals LP | $135 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-12-12 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-12-12 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-12-12 | GlaxoSmithKline, LLC. | $2 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-12-11 | BioCryst US Sales Co., LLC | $24 | Food and Beverage | In-kind items and services | ORLADEYO Drug, Immunology | 2024 | |
| 2024-12-10 | Grifols USA, LLC | $24 | Food and Beverage | In-kind items and services | Xembify Biological, Immunology and Neurology | 2024 | |
| 2024-12-10 | Takeda Pharmaceuticals U.S.A., Inc. | $20 | Food and Beverage | In-kind items and services | CUVITRU Biological, IMMUNOLOGY | 2024 |
The latest 200 records of 892.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-10 | AstraZeneca Pharmaceuticals LP | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC. | $9,467 | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do no | 2025 |
| 2025-05-08 | Eli Lilly and Company | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $2,273 | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITI | 2025 |
| 2024-07-05 | Eli Lilly and Company | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $5,588 | AN OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH MODERATE-T | 2024 |
| 2024-02-22 | Galderma Laboratories, L.P. | Interspond Llc | $3,000 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With M | 2024 |
| 2024-01-01 | Novartis Pharmaceuticals Corporation | GEORGIA POLLENS CLINICAL RESEARCH | $770 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Ef | 2024 |
| 2023-04-25 | PFIZER INC. | International Clinical Research Tennessee LLC | $2,416 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2023 |
| 2023-03-25 | PFIZER INC. | International Clinical Research Tennessee LLC | $2,770 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2023 |
| 2023-03-03 | Grifols Biologicals LLC | GEORGIA POLLENS CLINICAL RESEARCH | $10,556 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects | 2023 |
| 2023-02-24 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,344 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2023 |
| 2023-01-25 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $210 | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2023 |
| 2023-01-25 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $210 | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2023 |
| 2023-01-15 | Novartis Pharmaceuticals Corporation | GEORGIA POLLENS CLINICAL RESEARCH | $330 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Ef | 2023 |
| 2023-01-07 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,344 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2023 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | Interspond Llc | $29 | PONENTE A Multicenter Open-label Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to | 2022 |
| 2022-11-05 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,344 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2022 |
| 2022-10-12 | AstraZeneca Pharmaceuticals LP | Interspond Llc | $500 | PONENTE A Multicenter Open-label Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to | 2022 |
| 2022-10-08 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,344 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2022 |
| 2022-09-23 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,344 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2022 |
| 2022-09-02 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $771 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2022 |
| 2022-09-02 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $780 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2022 |
| 2022-09-02 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $2,702 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2022 |
| 2022-08-18 | ABBVIE INC. | Interspond Llc | $3,500 | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | 2022 |
| 2022-08-11 | ABBVIE INC. | Interspond Llc | $1,884 | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | 2022 |
| 2022-08-05 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $800 | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2022 |
| 2022-08-05 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $850 | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2022 |
| 2022-07-09 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,344 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2022 |
| 2022-07-05 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $291 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2022 |
| 2022-05-24 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,344 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2022 |
| 2022-05-05 | ABBVIE INC. | Interspond Llc | $2,324 | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | 2022 |
| 2022-04-19 | Grifols Biologicals LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $342 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2022 |
| 2022-04-14 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,344 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2022 |
| 2022-03-23 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $291 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2022 |
| 2022-03-23 | Octapharma USA, Inc. | GEORGIA POLLENS CLINICAL RESEARCH | $5,224 | SCGAM-06 | 2022 |
| 2022-03-23 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $291 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2022 |
| 2022-03-23 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $355 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2022 |
| 2022-03-17 | Grifols Biologicals LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $21,481 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2022 |
| 2022-02-17 | Eli Lilly and Company | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $11,465 | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITI | 2022 |
| 2022-02-15 | ABBVIE INC. | Interspond Llc | $1,884 | A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up | 2022 |
| 2022-02-09 | ABBVIE INC. | Interspond Llc | $1,000 | A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up | 2022 |
| 2022-02-09 | Novartis Pharmaceuticals Corporation | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $10,877 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF REMIBRUTINIB (LOU064) TO INVESTIGATE THE EF | 2022 |
| 2022-02-05 | PFIZER INC. | International Clinical Research Tennessee LLC | $2,688 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2022 |
| 2022-02-01 | Octapharma USA, Inc. | GEORGIA POLLENS CLINICAL RESEARCH | $1,219 | SCGAM-06 | 2022 |
| 2022-01-21 | Eli Lilly and Company | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $120 | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITI | 2022 |
| 2022-01-13 | Eli Lilly and Company | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $7,084 | AN OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH MODERATE-T | 2022 |
| 2022-01-03 | AstraZeneca Pharmaceuticals LP | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC. | $30,384 | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do no | 2022 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | Interspond Llc | $199 | PONENTE A Multicenter Open-label Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to | 2021 |
| 2021-12-28 | Octapharma USA, Inc. | GEORGIA POLLENS CLINICAL RESEARCH | $1,381 | SCGAM-06 | 2021 |
| 2021-12-16 | Grifols Biologicals LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $19,804 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-12-13 | ABBVIE INC. | Interspond Llc | $2,553 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects w | 2021 |
| 2021-12-08 | LEO Pharma AS | GEORGIA POLLENS CLINICAL RESESARCH CENTERS INC | $4,636 | LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | 2021 |
| 2021-11-23 | PFIZER INC. | International Clinical Research Tennessee LLC | $2,421 | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF A | 2021 |
| 2021-11-23 | Grifols Biologicals LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $85 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-11-10 | Grifols Therapeutics LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $5,174 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-11-05 | PFIZER INC. | International Clinical Research Tennessee LLC | $350 | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF A | 2021 |
| 2021-11-05 | PFIZER INC. | International Clinical Research Tennessee LLC | $4,032 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2021 |
| 2021-10-13 | Grifols Therapeutics LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $2,587 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-10-12 | Octapharma USA, Inc. | GEORGIA POLLENS CLINICAL RESEARCH | $4,424 | SCGAM-06 | 2021 |
| 2021-10-07 | Grifols Therapeutics LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $3,880 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-09-30 | Grifols Therapeutics LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $25,284 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-09-29 | Octapharma USA, Inc. | GEORGIA POLLENS CLINICAL RESEARCH | $653 | SCGAM-06 | 2021 |
| 2021-09-28 | LEO Pharma AS | GEORGIA POLLENS CLINICAL RESESARCH CENTERS INC | $1,643 | LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | 2021 |
| 2021-09-27 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $291 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2021 |
| 2021-09-27 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $355 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2021 |
| 2021-09-22 | PFIZER INC. | International Clinical Research Tennessee LLC | $614 | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF A | 2021 |
| 2021-09-21 | PFIZER INC. | ELIAS RESEARCH ASSOCIATES LLC | $1,000 | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF A | 2021 |
| 2021-09-09 | ABBVIE INC. | Interspond Llc | $1,961 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects w | 2021 |
| 2021-09-08 | LEO Pharma AS | GEORGIA POLLENS CLINICAL RESESARCH CENTERS INC | $3,076 | LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | 2021 |
| 2021-09-07 | Grifols Therapeutics LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $12,642 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-09-04 | PFIZER INC. | International Clinical Research Tennessee LLC | $3,190 | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF A | 2021 |
| 2021-08-18 | AstraZeneca Pharmaceuticals LP | Interspond Llc | $3,389 | PONENTE A Multicenter Open-label Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to | 2021 |
| 2021-08-06 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,804 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2021 |
| 2021-08-05 | Grifols Biologicals LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $513 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-08-05 | Grifols Therapeutics LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $25,284 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-08-04 | ABBVIE INC. | Interspond Llc | $2,000 | A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficac | 2021 |
| 2021-07-20 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $210 | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2021 |
| 2021-07-20 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $210 | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topi | 2021 |
| 2021-07-14 | LEO Pharma AS | GEORGIA POLLENS CLINICAL RESESARCH CENTERS INC | $13,008 | LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | 2021 |
| 2021-07-13 | Octapharma USA, Inc. | GEORGIA POLLENS CLINICAL RESEARCH | $2,326 | SCGAM-06 | 2021 |
| 2021-07-01 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $355 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2021 |
| 2021-06-30 | ABBVIE INC. | Interspond Llc | $2,050 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects w | 2021 |
| 2021-06-29 | Grifols Therapeutics LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $36,701 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-06-23 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,344 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2021 |
| 2021-06-23 | LEO Pharma AS | GEORGIA POLLENS CLINICAL RESESARCH CENTERS INC | $2,115 | TRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS | 2021 |
| 2021-06-16 | LEO Pharma AS | GEORGIA POLLENS CLINICAL RESESARCH CENTERS INC | $1,886 | TRALOKINUMAB: CONFIRMATORY TRIAL IN ADOLESCENTS | 2021 |
| 2021-06-05 | PFIZER INC. | International Clinical Research Tennessee LLC | $3,822 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2021 |
| 2021-06-03 | ABBVIE INC. | Interspond Llc | $600 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects w | 2021 |
| 2021-06-01 | ABBVIE INC. | Interspond Llc | $2,430 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects w | 2021 |
| 2021-05-27 | AstraZeneca Pharmaceuticals LP | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC. | $17,090 | The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do no | 2021 |
| 2021-05-25 | Grifols Therapeutics LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $15,186 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-05-12 | LEO Pharma AS | GEORGIA POLLENS CLINICAL RESESARCH CENTERS INC | $7,683 | LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | 2021 |
| 2021-05-12 | Takeda Pharmaceuticals U.S.A., Inc. | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $2,404 | EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | 2021 |
| 2021-05-08 | PFIZER INC. | International Clinical Research Tennessee LLC | $3,606 | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF A | 2021 |
| 2021-05-08 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,711 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2021 |
| 2021-05-05 | Grifols Therapeutics LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $25,311 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-04-29 | ABBVIE INC. | Interspond Llc | $3,656 | A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects w | 2021 |
| 2021-04-22 | PFIZER INC. | International Clinical Research Tennessee LLC | $1,393 | A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF A | 2021 |
| 2021-04-22 | Octapharma USA, Inc. | GEORGIA POLLENS CLINICAL RESEARCH | $5,280 | SCGAM-06 | 2021 |
| 2021-04-22 | Regeneron Pharmaceuticals, Inc. | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $2,000 | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | 2021 |
| 2021-04-09 | Grifols Therapeutics LLC | GEORGIA POLLENS CLINICAL RESEARCH CENTERS INC | $18,983 | A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects | 2021 |
| 2021-04-09 | SANOFI US SERVICES INC. | GEORGIA POLLENS CLINICAL RESEARCH | $291 | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Albany, GA, county Dougherty County, GA, state Georgia; placed by its city name.
| Measure | Place (city or town) Albany, GA | County Dougherty County, GA | State Georgia |
|---|---|---|---|
| Population B01003 | 67,224 | 83,091 | 10,940,407 |
| Population, 2020 census P1 | 69,647 | 85,790 | 10,711,908 |
| Median age B01002 | 34.9 | 36.6 | 37.6 |
| Under 18 B01001 | 24.8% | 24.1% | 23.2% |
| 65 and over B01001 | 16.3% | 17.4% | 15.0% |
| Households B11001 | 27,538 | 34,280 | 4,074,366 |
| Foreign born B05002 | 2.0% | 2.3% | 11.2% |
| Median household income B19013 | $47,240 | $49,044 | $77,353 |
| Median family income B19113 | $52,662 | $59,329 | $93,754 |
| Per capita income B19301 | $25,040 | $27,422 | $40,924 |
| Poverty rate B17001 | 27.5% | 25.0% | 13.4% |
| Unemployment rate B23025 | 11.2% | 10.2% | 5.1% |
| Civilian labor force B23025 | 28,481 | 35,647 | 5,496,061 |
| Mean commute (minutes) B08013 | 19.7 | 20.0 | 28.3 |
| Bachelor's degree or higher B15003 | 21.4% | 22.8% | 34.9% |
| Housing units B25001 | 32,959 | 40,653 | 4,541,835 |
| Owner-occupied B25003 | 37.7% | 45.3% | 65.7% |
| Renters B25003 | 62.3% | 54.7% | 34.3% |
| Median home value B25077 | $124,300 | $134,400 | $303,300 |
| Median gross rent B25064 | $931 | $935 | $1,393 |
| White, not Hispanic B03002 | 17.4% | 22.8% | 49.1% |
| Black B03002 | 76.4% | 70.2% | 30.7% |
| Hispanic or Latino B03002 | 2.7% | 3.3% | 11.0% |
| Asian B03002 | 0.6% | 0.7% | 4.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 3.3% in Sep 2026 (3.4% a year earlier); per capita personal income $65,111 in 2025, up 26% in five years (+1.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Albany, GA.
Comments